TrialProstate cancer and prostatic diseases2024

Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel.

Primo N Lara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.